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Abstract
Background: Scotland introduced PCV7 and PCV13 immunisation in young children in 2006 and 2010 respectively.
One recent study from the United States reported a decrease in hospitalisation rates for all-cause pneumonia most
notably in adults older than 75 years of age following PCV7 introduction in the US child population. We aimed to
examine the effect of PCV7 and PCV13 on hospitalisation rates for all-cause pneumonia across all age groups in
Scotland.
Methods: We linked hospital records and death certification datasets for the entire Scottish population for the
period 2000 to 2012. We included all cases where the primary / secondary diagnosis was pneumonia. Differences in
hospital admission rates for pneumonia by age group were calculated using the difference in average annual rates
for each period.
Results: We estimated that all-cause pneumonia hospitalisation rates in children <2 years decreased by about 30 %
in the post-PCV-13 period compared with the pre-PCV period. However, in adults aged 75–84 years and ≥85 years,
all-cause pneumonia hospitalisation rates increased by 63 and 46 % respectively in the post-PCV 13 period
compared to the pre-PCV period. This resulted in an additional 7000 hospitalisations across all age groups in
Scotland in 2012 about half of which were in adults >75 years. At the same time, the median length of hospital
stay decreased by a third in children <2 years and by about 20 % in adults >75 years in the post-PCV13 period
compared to the pre-PCV period. Additionally, there was an 11 % reduction in deaths due to all-cause pneumonia,
and 30 % reduction in pneumococcal hospitalisations across all age groups in the post-PCV13 period compared
with pre-PCV period.
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Discussion: The modest and sustained decline in the rates of hospitalisation for all-cause pneumonia in children
and the reduction in proportion of pneumonia hospitalisations in children coded as pneumococcal disease in the
post-PCV period should alleviate concerns that pneumococcal serotype replacement may have resulted in an
increased pneumonia burden in this age group. The indirect impact of child PCV immunisation in those not
vaccinated (in terms of reduction in all-cause pneumonia hospitalisations in the elderly) has not been seen in
Scotland. Our results are likely to be confounded by changes in clinical coding and healthcare practices over the
same period.
Conclusions: Our results illustrate that health care planners cannot, with confidence, predict indirect PCV vaccine
impacts on hospitalisations. IPD surveillance across all age groups is needed to assess the indirect effects of PCV in
the community.
Keywords: Pneumococcal conjugate vaccine, Indirect effects, All-cause pneumonia hospitalisations, Pneumococcal
hospitalisations, Pneumonia mortality
Background
Globally, lower respiratory tract infections (primarily
pneumonia) were the second leading cause of morbidity
and fourth leading cause of mortality across all age
groups in 2013 [1]. The burden of pneumonia is dispro-
portionately higher in young children and the elderly
(above 65 years of age) [2, 3]. In general, mortality due
to pneumonia across all ages has declined substantially
(22 (95 % CI 16 to 30) percent) between 1990 and 2013
[1]. Prior to the introduction of the pneumococcal con-
jugate vaccine (PCV) in the US, hospitalisation rates for
pneumonia in the elderly (65 to 84 years) increased by
about 20 % in the 15 year period between 1988–1990
and 2000–2002 [3]. Similar increases (over a similar
though abbreviated period) have been reported in Eng-
land, Denmark, and the Netherlands [4–6]. The increase
in this age group has been attributed to an ageing popu-
lation, increase in the prevalence of comorbidities, and
changes in coding and hospital admission practices [4].
The prevalence of Streptococcus pneumoniae in adults
with community-acquired pneumonia (CAP) has declined
sharply since the advent of antibiotics. Data from Medicare
(for year 2009) indicate that about 7.6 % of CAP hospitali-
sations in the elderly (aged 65 years and above) in the
United States can be attributed to Streptococcus pneumo-
niae [7]. Therefore, pneumococcal polysaccharide vaccine
(PPV) was introduced in Scotland in the winter of 2003 to
persons aged 65 years and above, and high risk individuals
(i.e., those with co-morbidities). Following the introduction
of PCV7 into the national child immunisation schedules in
the US and England and Wales, there has been a decrease
in the overall incidence of invasive pneumococcal disease
(IPD) across all age groups [8, 9]. PCV7 was introduced
into the Scottish child immunisation schedule in September
2006 at the age of 2 and 4 months with a booster dose at
around 13 months. Severe pneumococcal disease (using
IPD as a surrogate) was increasing in Scotland in the period
prior to introduction of PCV7 (from 559 cases in 2000 to
753 cases in 2006) [10]. After the introduction of PCV7,
and PCV13 later in 2010 (both using 2 + 1 dose schedule),
there has been a decrease in the number of IPD cases in
children younger than 5 years (from 753 cases in 2006 to
482 cases in 2012). It was expected that with the increased
uptake of PCV, there would be an increase in the circulat-
ing non-vaccine serotypes (NVT) [11, 12]. In the US, after
the introduction of PCV7, there was an increase in disease
(across all age groups especially in young children and eld-
erly) caused by NVT, most notably serotype 19 A [13]. In
addition, in 2013, Griffin and colleagues demonstrated a de-
crease in hospitalisation rates for all-cause pneumonia
(henceforth referred to as pneumonia) not only in children
but also across all age groups, most notably in adults older
than 75 years of age following introduction PCV7 in the
US child population [14]. We aimed to examine the effect
of PCV7 and PCV13 on hospitalisation rates for pneumo-
nia across all age groups in Scotland and examine the
generalizability of Griffin and colleagues’ findings.
Methods
Data sources
Scotland has an excellent health service data system with
an ability to perform high quality linkage (through a
unique personal identifier attached to health records –
the Community Health Index [CHI] number) of individ-
ual hospitalisation, laboratory and death certification
data which permits individual patient data analysis and
follow-up. National Services Scotland is responsible for
maintaining these data and ensuring high data quality,
consistency and coverage and appropriate levels of data
governance (http://www.isdscotland.org/). The Scottish
Morbidity Record (SMR01) comprises episode level data
on hospital inpatient and day case discharges from acute
specialties from hospitals in Scotland. The dataset con-
tains patient identifiers such as the CHI number, demo-
graphic details such as postcode together with health
record data (episode management details and general
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clinical information). These data have been available
electronically (for research purposes) since 1981. Usu-
ally, when inpatients and day cases are transferred to an-
other specialty within the same hospital or are
transferred to another hospital, a new record on SMR01
is generated. However, in this analysis, we used continu-
ous inpatient stay (CIS) data by linking SMR01 episodes
for each patient. This created “linked” individual patient
histories (which includes transfers between hospitals,
specialties, and consultants). This integrated measure
documents the length of continuous hospital care epi-
sodes. Data from SMR01 on hospital admissions for
pneumonia, hospitalisation, discharge diagnosis of
pneumococcal pneumonia, readmissions within 14 days,
sex, age, health board area, length of stay; and mortality
data from General Register Office of Scotland (GRO99B)
were collected.
Definition of hospitalisation for pneumonia
Hospitalisation for pneumonia was defined in accord-
ance with ICD 10 procedures. CIS data were selected for
inclusion in the study if the patient had a primary diag-
nosis of pneumonia OR a primary diagnosis of sepsis,
meningitis or empyema, with a diagnosis of pneumonia
in any subsequent diagnostic position. A list of ICD 10
codes used to qualify diagnosis for all-cause pneumonia,
meningitis, empyema, septicemia and pneumococcal
pneumonia are detailed in Additional file 1: Table S1.
We considered hospital readmissions within 14 days of
the primary admission as part of the same event [15].
Statistical analysis
SMR01 data from 2000 through 2012 (epidemiological
year July-June) were used as numerator data in estimat-
ing annual hospitalisation rates for pneumonia. We con-
structed a cohort of patients by linking hospital records
and death certification datasets. We used the following
age groups for analysis: children aged below two years, 2
to 4 years, 5 to 17 years, adults aged 18 to 39 years, 40
to 64 years, 65 to 74 years, 75 to 84 years, and 85 years
or older. We stratified the analysis into three different
time periods: 2000 through 2005 were considered as the
pre-PCV period; 2006 was treated as transition year, as
this was the year that PCV was introduced nationally
and therefore excluded from the analysis; 2007 through
2009 as the post-PCV7 period; and 2010 through 2012
as the post-PCV13 period (as PCV 13 was introduced
nationally in April 2010). We used population by Scot-
tish NHS Health Board of residence provided by ISD
(based on official national census data and estimates) as
population denominator data in the calculation of an-
nual hospital admission rates (by age group) and re-
ported these per 100,000 persons per year. Differences
in hospital admission rates by age group were calculated
using the average annual rates for each period, and the
observed and expected rates were compared. We used
these data to derive the percentage difference in relative
rates. Where no data were available for a particular
health board (age/sex/year combination), most fre-
quently seen in the case of the smallest Health Boards,
we assumed that there were no cases of pneumonia, ra-
ther than regarding these as missing data. Where the
Health Board was given as “Other”, we considered that
these could be due to two reasons: data were missing
but the patient was resident in Scotland; or patient was
a resident of another country but was treated in
Scotland. We considered both scenarios in the analysis.
All data analyses were conducted using SPSS V19.0
(IBM, NY, USA) and SAS V9.2 (SAS institute Inc., NC,
USA).
Results
From 2000 to 2012, there were 153,636 new hospitalisa-
tion episodes for pneumonia across Scotland. In addition
to these hospitalisations, there were 4551 readmissions
within 14 days of discharge. Pneumonia was the first
listed diagnosis for 97.6 % of these hospitalisations. Sep-
sis was the first listed diagnosis for 1.9 %, and meningitis
and empyema the first listed diagnosis each for 0.3 and
0.2 % respectively. Prior to the introduction of PCV, we
observed a gradual increase in the rates of pneumonia
hospitalisation in children aged below 5 years (Fig. 1). A
similar pattern was seen in adults aged over 75 years
(Fig. 2). Across the twelve year period (2000–2012), the
annual rates of pneumonia hospitalisations were highest
in adults aged above 65 years and children aged below
two years (Table 1). In the pre-PCV period, the rates for
pneumonia hospitalisation in adults aged 75 to 84 years
and 85 years and above, were approximately 3 and 6.5
fold higher respectively than those in children aged less
than two years. In the post-PCV 7 period, this difference
increased to about 5 and 9 fold respectively; and further
increased to about 7 and 13 fold respectively in the post-
PCV 13 period. This pattern was sustained even when
data from “other” Health Boards were excluded (Add-
itional file 1: Figures S1 and S2).
The pneumonia hospitalisation rates in children
aged less than 2 years decreased by about 30 % in
the post-PCV 13 period compared to the pre-PCV
period (Fig. 3). Pneumonia hospitalisations in this age
group declined by about 19 % in the post-PCV7
period (compared to pre-PCV) and by about 14 % in
the post-PCV13 period (compared to post-PCV7).
However, the rates remained largely unchanged in the
age groups 2–39 years. We saw that in the older age
groups, the pneumonia hospitalisation rates increased
steadily in the post-PCV period (greater increase
post-PCV13 compared to post-PCV7). In adults aged
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75–84 years and 85 years and above, the pneumonia
hospitalisation rates increased by 63 and 46 % re-
spectively in the post-PCV 13 period compared to the
pre-PCV period (Table 1, Additional file 1: Table S2).
This translates to an absolute increase of about 7000
hospitalisations across all age groups in Scotland in
2012. Half of this increase was observed in age
groups older than 74 years (increase of 2200 and
Fig. 1 Pneumonia hospitalisations in Scotland from July 2000 to June 2012 in children. Panel a shows annual rates of hospitalisation for pneumonia
from 2000 to 2012. PCV 7 was introduced in 2006 and PCV 13 in 2010. Panel b shows annual rates of hospitalisation for 2000 to 2005, 2007 to 2009
and 2010 to 2012 for all children (including those coded as “other” health boards)
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1300 hospitalisations in the age group 75–84 years
and 85 years and above respectively (Table 2).
We observed that during 2000–2012, the mean and
median length of stay (LOS) increased with age
(Additional file 1: Figure S3 and Additional file 1: Table
S3). The pattern of longer stays (defined as more than
30 days) is the familiar “hook” pattern with the lowest
number being in the 2–4 year age group and then
Fig. 2 Pneumonia hospitalisations in Scotland from July 2000 to June 2012 in adults. Panel a shows annual rates of hospitalization for pneumonia
from 2000 to 2012. PCV 7 was introduced in 2006 and PCV 13 in 2010. Panel b shows annual rates of hospitalization for 2000 to 2005, 2007 to
2009 and 2010 to 2012 for all adults (including those coded as “other” health boards)
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increasing with age (Additional file 1: Table S4). This
pattern is sustained even if a lower threshold (of stays
more than 14 days) is used to define longer hospitalisa-
tion. In the post-PCV 13 period, median length of hos-
pital stay decreased by a third in children aged below
2 years and by 22 and 18 % in the age groups 75–84
years and 85 years and above respectively compared with
the pre-PCV period (Table 1). We also observed that al-
though the distribution of length of stay in hospital
(across all age groups) remained the same in the pre-
PCV and post-PCV13 period, there was a significantly
higher proportion of patients with stays longer than
14 days in the former (24.8 % vs 20.9 %, p < 0.001) (Add-
itional file 1: Table S5). When the analysis was stratified
by age, the pattern of significantly higher proportion of
patients with stays longer than 14 days was seen only in
adults aged over 40 years (Additional file 1: Table S5).
The proportion of pneumonia hospitalisations coded
as pneumococcal disease decreased substantially across
all age groups in the post-PCV13 period (Table 1). The
most dramatic reduction was seen in children aged
below 5 years (about a two-thirds reduction) while in
the elderly aged 85 years only a one-third reduction was
demonstrated. At a population level, we observed 29
(95 % CI 22 to 35) percent reduction in pneumococcal
admissions across all age groups in Scotland in the post-
PCV13 period compared to pre-PCV period. However,
this varied by age group -while there was a 70 % reduc-
tion in pneumococcal hospitalisations in children aged
below 5 years in the post-PCV13 period compared to
pre-PCV period, older age groups experienced a more
modest reduction (21 and 25 % in those 65–74 years
and 75 years and above respectively) (Additional file 1:
Table S6).
We observed a substantial reduction in the proportion
of deaths due to pneumonia (as a primary cause) across
all age groups in the post-PCV13 period when compared
to pre-PCV period. In elderly patients aged 75–84 and
85 years and above there was a decrease of about 53 and
40 % respectively (Table 1). This pattern was sustained
when deaths from pneumonia were defined more
broadly and included all deaths in which pneumonia was
mentioned on the death certificate but was not recorded
as the underlying cause of death (Additional file 1: Table
Table 1 Rates of hospitalisation, length of hospital stay, and rates of in-hospital death related to pneumonia in Scotland 5 years be-
fore introduction of PCV 7 and three years after introduction of PCV 13
Age (years) <2 2–4 5–17 18–39 40–64 65–74 75–84 85+
Pneumonia Hospitalisation rate /100Ka (95 % CI)
2000–2005 293 (280–306) 181 (173–190) 43 (41–45) 53 (51–54) 112 (110–114) 373 (365–380) 875 (861–889) 1909 (1872–1946)
2010–2012 206 (191–221) 177 (166–188) 45 (42–48) 62 (59–64) 182 (179–186) 634 (621–647) 1426 (1402–1451) 2785 (2728–2842)
Lengths of hospital stay (days). Median (IQR)
2000–2005 3 (1–5) 2 (1–4) 3 (1–5) 4 (2–6) 5 (3–10) 7 (4–14) 9 (4–19) 11 (5–25)
2010–2012 2 (1–5) 2 (1–4) 2 (1–5) 3 (1–6) 5 (2–9) 6 (3–12) 7 (4–15) 9 (4–19)
Lengths of hospital stay (days) incl. readmissions within 14 days. Median, IQR
2000–2005 3 (1–5) 2 (1–4) 3 (1–5) 4 (2–7) 5 (3–11) 7 (4–15) 9 (4–20) 12 (4–25)
2010–2012 2 (1–5) 2 (1–4) 2 (1–5) 3 (1–7) 5 (2–9) 6 (3–12) 8 (4–16) 9 (4–19)
Reasons for admission coded as pneumococcal disease. %, 95 % CI
2000–2005 9.3 (8.1–10.7) 3.3 (2.5–4.2) 4.1 (3.4–5.1) 6.8 (6.1–7.5) 6.1 (5.7–6.6) 3.8 (3.4–4.1) 2.3 (2.0–2.5) 1.1 (1.0–1.4)
2010–2012 3.3 (2.3, 4.9) 1.1 (0.6–1.9) 2.5 (1.7–3.6) 3.5 (2.9–4.3) 2.9 (2.6–3.3) 1.7 (1.4–2.0) 1.0 (0.8–1.2) 0.7 (0.5–0.9)
Deaths from pneumonia (primary cause, all patients)b %, 95 % CI
2000–2005 0 0.06 (0.008, 0.4) 0.2 (0.1, 0.6) 0.7 (0.5, 1.0) 3.5 (3.2, 3.8) 6.9 (6.5, 7.4) 13.1 (12.5, 13.6) 25.8 (24.9, 26.6)
2010–2012 0 0 0.3 (0.1, 0.9) 0.3 (0.1, 0.6) 1.4 (1.2, 1.7) 3.4 (3.0, 3.7) 6.2 (5.8, 6.6) 15.7 (15.0, 16.5)
Deaths from pneumonia as proportion of all deaths (primary cause)c %, 95 % CI
2000–2005 0 2.4 (0.3, 15.1) 3.1 (1.3, 7.4) 5.2 (3.7, 7.2) 7.4 (6.7, 8.2) 8.7 (8.1, 9.3) 14.1 (13.5, 14.7) 26.3 (25.4, 27.2)
2010–2012 0 0 11.1 (3.6, 29.3) 4.3 (2.2, 8.4) 6.0 (5.1, 7.1) 8.2 (7.4, 9.2) 12.0 (11.2, 12.8) 24.0 (22.9, 25.1)
Deaths from pneumonia (any cause, all patients)d %, 95 % CI
2000–2005 0.8 (0.5, 1.3) 0.6 (0.3, 1.0) 2.3 (1.8, 3.0) 3.7 (3.2, 4.3) 18.8 (18.1, 19.5) 36.9 (35.9, 37.8) 52.8 (52.0, 53.6) 66.1 (56.1, 67.0)
2010–2012 0.7 (0.3, 1.6) 0.2 (0.05, 0.8) 2.1 (1.4, 3.2) 2.4 (1.9, 3.1) 8.5 (8.0, 9.1) 14.9 (14.2, 15.6) 21.6 (20.9, 22.3) 36.1 (35.1, 37.1)
aThe hospitalisation rates have been calculated after excluding data where patient’s health board was coded as “other”
bDeaths with pneumonia as a primary cause as a proportion of the whole population
cDeaths with pneumonia as a primary cause as a proportion of the deaths reported in this population
dDeaths with pneumonia as any cause as a proportion of the whole population
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S7). At a population level, there was an overall 11 % re-
duction in deaths in post-PCV13 period compared to
pre-PCV period, with a 19 and 12 % reduction in those
aged 65–74 years and 75 years and above respectively
(Additional file 1: Table S8). We also observed a 7 % re-
duction in pneumococcal deaths across all age groups
with an 18 and 12 % reduction in the 65–74 years and
75 years and above age groups respectively (Additional
file 1: Table S9).
Discussion
This is the first national study to report the impact of a
child PCV immunisation programme on pneumonia
hospitalisations across all age groups. Our results are
based on a Scottish national dataset for a 12 year period
(2000–2012). We observed modest and sustained de-
clines in the childhood hospitalisation rates for pneumo-
nia in the six years following the introduction of PCV 7
and 13. This should alleviate concerns regarding
Table 2 Difference in pneumonia hospitalisation rates in Scotland comparing pre-PCV7 and post-PCV13 periods. With absolute










rates per 100,000 population,
PrePCV7 vs LatePCV7/PCV13








from 2000 to 2006
distributionb
Estimated absolute change in
number of hospitalisations,
2012 (observed – expected),
n, 95 % CI
<2 240 119,275 −87.0 (−107.0, −67.0) −29.7 (−36.5, −22.8) 349.8 −109.8 (−125.7, −94.0)
2–4 283 176,596 −4.8 (−19.0, 9.0) −2.8 (−10.5, 5.1) 320.9 −37.9 (−52.7, −23.0)
5–17 262 742,593 2.1 (−1.0, 5.4) 4.9 (−2.3, 12.6) 317.8 −55.8 (−69.9, −42.5)
18–39 783 1,506,987 9.1 (6.4, 11.9) 17.4 (12.2, 22.7) 789.7 −6.7 (−29.3, 15.9)
40–64 3521 1,842,398 70.3 (66.2, 74.4) 62.9 (59.2, 66.6) 2058.0 1463.0 (1424.4, 1500.0)
65–74 3467 507,265 262.0 (247.2, 276.7) 70.4 (66.4, 74.3) 1888.5 1578.5 (1541.4, 1615.5)
75–84 4888 309,244 551.6 (523.4, 579.7) 63.0 (59.8, 66.3) 2705.6 2182.4 (2138.8, 2226.0)
85+ 3372 109,242 876.4 (808.7, 944.1) 45.9 (42.4, 49.5) 2085.4 1286.6 (1246.2, 1327.0)
All
ages
16,816 5,313,600 110.3 (107.2, 113.3) 59.6 (57.9, 61.2) 9835.5 6980.5 (6895.5, 7060.2)
aAs percentage of 2000–2006 (PrePCV7) data
bDerived from hospitalisation rate from PrePCV7 data applied to the 2012 population figures
Fig. 3 Average Annual Rates of Scottish hospitalisations for Pneumonia before and after the introduction of PCV7 and PCV13
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pneumococcal serotype replacement, as we have found
no evidence of increased pneumonia burden in children
following the introduction of PCV. We also observed a
33 % reduction in the median length of stay in hospital
for pneumonia in children aged below 2 years. However,
we noted a dramatic and progressive increase in pneu-
monia hospitalisations in adults, most notably in those
aged above 65 years. This translates to an annual in-
crease of about 7000 hospital admissions for pneumonia
across Scotland. This increase in hospital admissions is
accompanied by contrasting decreases in the length of
stay in hospital, the proportion of hospital admissions
coded as pneumococcal pneumonia and pneumonia
mortality in adults aged over 75 years.
We found a gradual increase in the annual pneumonia
hospitalisation rates for children aged below 5 years in
the pre-PCV period (Fig. 1). These results are consistent
with those reported in previous analyses of pneumonia
trends in Scotland and England prior to the introduction
of PCV [16, 17]. Koshy and colleagues concluded that
this was likely due to a true increase in disease incidence
(reflected in hospitalisation rates), as it was consistent
with similar reports elsewhere.
We reported a 30 % decline in pneumonia hospitalisa-
tions in children aged below 2 years following the intro-
duction of first PCV 7 and later PCV 13, which is
reassuringly consistent with results of clinical trials in-
vestigating the effectiveness of PCV against radiograph-
ically confirmed WHO Primary Endpoint Pneumonia
(bacterial) pneumonia [18, 19]. A previous study from
England reported 19 to 22 % decline in hospitalisation
rates for bacterial pneumonia in children aged below
15 years in the two years post-PCV7 (2007 and 2008)
[17]. Our results for the six years post-PCV in children
aged below 18 years are consistent with those reported
by Griffin and colleagues for US populations in the first
decade after introduction of PCV 7 [14] (Panel 1).
However, in older adults, our results contrast markedly
from findings reported by Griffin and colleagues [14].
We estimated that in Scotland, the hospitalisation rate
for all-cause pneumonia in adults aged 65–74 years in
the post-PCV13 period was 640.4 per 100,000 persons
per year compared to 376.6 per 100,000 persons per year
in the pre-PCV period. Similar increases were seen in
the age groups 75 years and above. By contrast, Griffin
and colleagues reported a slight decrease in the rate of
hospitalisation in the post-PCV7 period (1208 compared
to 1293 per 100,000 persons per year) in the 65–74 year
age group. More substantial decreases were reported in
the older age groups (75 years and above). In Scotland,
this translates to an additional 7000 hospital admissions
for pneumonia in post-PCV period, compared to
112,000 fewer hospitalisations in U.S adults. Griffin and
colleagues attributed these declines to the indirect “herd
immunity” effect of PCV on pneumococcal pneumonia.
We did however observe a substantial decline in the
proportion of pneumonia hospitalisations coded as
pneumococcal disease across all age groups in the post-
PCV period. However, it is very likely that we may have
underestimated the impact of PCV on pneumococcal
pneumonia. This is because hospital discharge data are
based on clinical diagnoses recorded in patients’ medical
records and accurate diagnosis of pneumococcal pneu-
monia is difficult without isolation of S. pneumoniae
[20]. Notably, since 2010, we observed an increase in
both the hospitalisations for pneumococcal pneumonia
(numerator) and all-cause pneumonia (denominator) in
adults older than 65 years even though there was a de-
crease in the proportion of pneumonia cases coded as
pneumococcal pneumonia (Additional file 1: Table S11).
Extrapolating from the pneumonia hospitalisation rates
in the pre-PCV period, we calculated the (expected)
number of pneumonia hospitalisations assuming absence
of PCV immunisation in the period 2007–12. Unlike in
younger children, the expected number of pneumonia
hospitalisations during this period would have been
lower in older children (aged above 5 years) and adults.
Therefore, it appears that the impact of child PCV
immunization in Scotland on pneumonia hospitalisa-
tions has been limited to children aged younger than
5 years (Table 2).
There are several reasons why our results are not con-
sistent with those observed by Griffin and colleagues.
Firstly, this could be attributed to differences in coding
practices in both countries. The US Nationwide In-
patient Sample (NIS) database uses up to 15 diagnostic
positions, whereas ISD only uses up to 6 diagnostic posi-
tions. Therefore for a first diagnosis of meningitis, septi-
caemia or empyema, pneumonia could have been a
secondary diagnosis in one of 14 diagnostic positions in
the US study, but a secondary diagnosis in only one of 5
diagnostic positions in the present study. This could
mean that fewer cases of septicaemia, meningitis and
empyema were included as pneumonia cases in
Scotland. It has been reported that during 2003–09 in
the US there was an observed decrease in the coding for
a primary diagnosis of pneumonia, which was partially
compensated for by increases in coding for primary
diagnoses of other diseases e.g., sepsis and respiratory
failure [21]. Therefore, the decline in hospitalisations for
pneumonia reported in the US may be partially due to
an artefact of changes in diagnostic coding. In Scotland,
the percentage of hospitalisations with pneumonia as a
secondary diagnosis has remained almost static at 2.5 % in
the 2000–2005 period, 2.4 % in the 2007–2009 period and
2.5 % in the 2010–2012 period. Although the study by
Griffin and colleagues would have included cases with a
primary diagnosis of sepsis as pneumonia hospitalisation,
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they would not have included diagnoses that were coded
as respiratory failure [14]. Indeed, Lindenauer and col-
leagues have reported that when combined with diagnoses
of sepsis and respiratory failure, much more modest de-
clines were seen in the hospitalisation rates for pneumonia
[21]. Secondly, the US study was based on a 20 % sample
of US hospitals, whereas our study was based on inpatient
data from the whole of Scotland. Thirdly, the increasing
trend of adult pneumonia hospitalisations in Scotland
may be an artefact of changing healthcare practices. This
could have overcompensated for any declines in adult all-
cause pneumonia hospitalisations that may have been seen
as a result of the known herd effect of PCV [13]. Indeed,
there was a 10 % increase in all-cause hospitalisations (de-
fined using CIS) during our study period (2000–2012)
(data source: Information Services Division, National Ser-
vices Scotland in response to data request IR2015-01696).
Fourthly, the increase in pneumonia hospitalisations could
be attributed to improvement in coding practices (even
though ICD-10 codes have been in use in Scotland since
1996). Coding is also reported to have improved in Eng-
land [22] and may have contributed to the apparent in-
creases in pneumonia hospitalisations reported there [17].
In England and Wales, in the period 2000–10, there was
an improvement in case ascertainment for invasive bacter-
ial infections which is corroborated by a concomitant in-
crease in cases of other invasive bacterial infections
reported to Public Health England. Miller and colleagues
corrected for these changes by retrospectively inflating the
case count to the projected 2009–10 level of ascertain-
ment [9]. They found that without adjusting for these
changes there was little reported change in IPD incidence
(across all age groups except children younger than
5 years) after PCV introduction although PCV has been
demonstrated to have a substantial impact on IPD inci-
dence both in children and adults [23].
The National Audit Office (NAO) has reported an in-
creasing trend of emergency hospital admissions in
Scotland and the rest of the UK [24]. The increase was
thought to be partially due to an ageing population and
due to a tendency to treat patients as day cases or give
patients earlier discharge to reduce bed pressure, result-
ing in more readmissions. This is consistent with our
observation of a trend towards decreasing length of hos-
pital stay for patients with pneumonia. In England there
was a 40 % increase in pneumonia hospitalisations for
children aged less than 15 years between 1999 and 2010
[25]. Moreover, another study from England has re-
ported a 34 % increase in hospital admissions for pneu-
monia before the introduction of PCV, mainly for
pneumonias coded with an unspecified diagnosis [4].
Subsequent to changes to the general medical services
contracts in 2004, General Practitioners in the UK (in-
cluding Scotland) were no longer required to provide
out of hours services. In England and Wales, this has re-
sulted in a 32 % increase in A&E attendances between
2003–04 and 2013–14, translating into an 8 % growth in
the likelihood of being admitted to hospital after attend-
ing A&E during this period [26]. Indeed, patients may be
more likely to be sent to hospital by an unfamiliar doc-
tor [4]. This is likely to be true for Scotland as well.
With increased emergency department visits and refer-
rals there would be a greater diagnosis of pneumonias
that would have otherwise gone undiagnosed. We also
observed an overall increase in the percentage of hos-
pital readmissions for pneumonia from 2.0 % in 2000 to
3.6 % in 2012. We therefore considered episodes gener-
ated from readmissions within 14 days to be part of the
same event and consequently excluded them from our
primary analysis. However, when disaggregated by age
groups, we observed that the proportion of early read-
missions (within 14 days of discharge) decreased in
those younger than 40 years (the most substantial de-
crease of about 74 % being in children aged below
2 years) (Additional file 1: Table S9). The US study also
found a trend of decreasing hospital stays before and
after the introduction of PCV and found decreases in
pneumonia hospitalisation rates, even without adjusting
for readmissions [14].
The difference between our findings and those re-
ported by Griffin cannot be attributed to differences in
pneumococcal polysaccharide vaccine (PPV) coverage in
the two populations as they are likely to be similar for
Scotland and U.S. Limited PPV coverage data for
Scotland are available − the initial vaccination uptake
was estimated to be 65 % [27]. Estimates for England in-
dicate a coverage of about 69 % [28]. Similarly, PPV was
introduced in the US in 1997 for all individuals aged
65 years and above. Although recent coverage data are
not available, the data for 2005 estimate PPV coverage to
be about 64 % [29].
Conclusions
Our findings support the evidence on the impact of
PCV on pneumonia hospitalisations in children, indicat-
ing that vaccine impact in this national programme is
broadly consistent with predictions from vaccine trials.
It is reassuring that reductions in hospitalization have
persisted over 6 years with no evidence of negative indir-
ect effects (due to serotype replacement) eroding this
impact over this time period. This reduced proportion of
pneumonia hospitalisations in children coded as
pneumococcal disease post PCV13 introduction gives
further reassurance that there is not a substantial sero-
type replacement effect over the study period. The fail-
ure to note any positive indirect effect of infant PCV
vaccination on (pneumococcal) pneumonia in non-
vaccinated individuals observed through measurement
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of hospitalisations among older individuals is likely due
to contemporaneous changes in clinical practice and
coding as discussed above. This suggests that indirect ef-
fects of PCV on observed hospitalisations may be con-
text specific and demonstrates that health care planners
and health economists cannot, with confidence, predict
positive indirect PCV vaccine impacts on hospitalisa-
tions in their estimates of vaccine impact on health ser-
vice costs. IPD surveillance in all age groups is needed
to assess the indirect effects of PCV in the community.
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